Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
ATHE 
Alterity Therapeutics Ltd (ATHE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: ATHE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.42% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 60.36M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 3 | Beta 0.02 | 52 Weeks Range 2.52 - 7.00 | Updated Date 01/9/2026 |
52 Weeks Range 2.52 - 7.00 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -223.35% | Operating Margin (TTM) -185.73% |
Management Effectiveness
Return on Assets (TTM) -28.09% | Return on Equity (TTM) -43.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 38630966 | Price to Sales(TTM) 11.1 |
Enterprise Value 38630966 | Price to Sales(TTM) 11.1 | ||
Enterprise Value to Revenue 113.99 | Enterprise Value to EBITDA 0.75 | Shares Outstanding 18125694 | Shares Floating 7038063195 |
Shares Outstanding 18125694 | Shares Floating 7038063195 | ||
Percent Insiders - | Percent Institutions 1.86 |
Upturn AI SWOT
Alterity Therapeutics Ltd
Company Overview
History and Background
Alterity Therapeutics Ltd. (formerly known as Tralance Ltd.) was founded in 2003 and is a clinical-stage biotechnology company focused on developing novel treatments for neurodegenerative diseases. The company's lead candidate, amantadine, is being investigated for its potential to improve cognitive function in patients with Alzheimer's disease and Parkinson's disease dementia. Significant milestones include progression into clinical trials and strategic partnerships.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Development of small molecule therapeutics targeting neurodegenerative diseases, with a primary focus on amantadine for Alzheimer's disease and Parkinson's disease dementia.
Leadership and Structure
Alterity Therapeutics Ltd. is led by a management team with expertise in drug development and the biotechnology sector. The company operates as a clinical-stage biopharmaceutical entity, with its research and development efforts concentrated on its lead drug candidate.
Top Products and Market Share
Key Offerings
- Amantadine (for Alzheimer's Disease and Parkinson's Disease Dementia): Amantadine is an existing drug repurposed for the treatment of cognitive impairment in patients with Alzheimer's disease and Parkinson's disease dementia. Market share data for amantadine specifically in these indications is not readily available as it is a repurposed drug. Competitors in the broader Alzheimer's and dementia treatment market include companies developing drugs like Aducanumab (Biogen), Lecanemab (Eisai/Biogen), and Donepezil (various manufacturers).
Market Dynamics
Industry Overview
The neurodegenerative disease market, particularly for Alzheimer's and Parkinson's, is characterized by a high unmet medical need and significant investment in research and development. The market is competitive with numerous companies pursuing various therapeutic approaches, including small molecules, biologics, and gene therapies.
Positioning
Alterity Therapeutics Ltd. is positioned as a clinical-stage company aiming to leverage the existing safety profile of amantadine to address cognitive deficits in Alzheimer's and Parkinson's disease dementia. Its competitive advantage lies in its focus on a well-characterized molecule and its ongoing clinical trials.
Total Addressable Market (TAM)
The TAM for Alzheimer's disease treatments is substantial and growing, estimated to be in the tens of billions of dollars globally. For Parkinson's disease dementia, the TAM is also significant. Alterity Therapeutics Ltd. is positioned to capture a portion of this market if its amantadine-based treatments prove effective and gain regulatory approval.
Upturn SWOT Analysis
Strengths
- Repurposing of an existing drug (amantadine) with a known safety profile.
- Focus on significant unmet medical needs in Alzheimer's and Parkinson's disease dementia.
- Experienced management team.
- Ongoing clinical trials to validate efficacy.
Weaknesses
- Clinical-stage company with no approved products.
- Dependence on the success of amantadine.
- Potential for competition from novel therapies.
- Financing risks associated with clinical development.
Opportunities
- Expanding therapeutic applications of amantadine.
- Partnerships with larger pharmaceutical companies for development and commercialization.
- Increasing global demand for effective neurodegenerative disease treatments.
- Advancements in diagnostic tools for earlier and more accurate patient identification.
Threats
- Clinical trial failures.
- Regulatory hurdles and delays.
- Emergence of superior or more cost-effective treatments.
- Intense competition in the neurodegenerative disease space.
- Changes in healthcare reimbursement policies.
Competitors and Market Share
Key Competitors
- Biogen (BIIB)
- Eisai Co., Ltd. (ESALY)
- Eli Lilly and Company (LLY)
- AbbVie Inc. (ABBV)
- Merck & Co., Inc. (MRK)
Competitive Landscape
Alterity Therapeutics Ltd. faces intense competition from large pharmaceutical companies with established R&D capabilities and significant market presence in the neurodegenerative disease space. Its advantage lies in potentially offering a more accessible and cost-effective treatment if amantadine proves efficacious, but it must overcome the significant development and regulatory hurdles.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Alterity Therapeutics Ltd. has been characterized by the progression of its clinical pipeline and the securing of funding. The company's focus has been on scientific advancement rather than revenue-driven growth.
Future Projections: Future projections are highly dependent on the success of its clinical trials for amantadine. Analyst estimates, if available, would likely focus on potential market penetration and revenue generation post-approval.
Recent Initiatives: Recent initiatives would likely include advancing amantadine through its clinical trial phases, seeking regulatory feedback, and exploring potential strategic partnerships or collaborations.
Summary
Alterity Therapeutics Ltd. is a clinical-stage biopharmaceutical company with a promising but unproven lead drug candidate, amantadine, for neurodegenerative diseases. Its strengths lie in repurposing an existing drug and addressing significant unmet medical needs. However, it faces considerable weaknesses as a clinical-stage entity, dependent on trial success and funding. The company must navigate a highly competitive market with established players and significant threats from regulatory hurdles and clinical failures.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Financial news websites
- Industry research reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. The biotechnology sector is inherently volatile, and stock performance is subject to significant risk. Investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alterity Therapeutics Ltd
Exchange NASDAQ | Headquaters Melbourne, VIC, Australia | ||
IPO Launch date 2002-09-05 | CEO & Director Dr. David A. Stamler M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | Website https://alteritytherapeutics.com |
Full time employees 9 | Website https://alteritytherapeutics.com | ||
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.